Arlene Morris
CIK 1362520 · CEO · last filed 2026-08-31
Arlene Morris is a CEO who has filed 85 SEC Form 4 insider transactions across 12 companies since 2007. The most recent filing, for COGT, was dated Aug 31, 2026. Across all open-market trades the lifetime net is −$18.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.0M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.01M
12
85
-$18.01M
Filer Profile
4001 MIRANDA AVE.
PALO ALTO, CA 94304
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| COGT | Director | 45,510 | $33.41 | $1.52M | -$1.69M | 7 | 2026-08-31 |
| PTN | Director | 41,580 | $11.80 | $490.6K | $28.7K | 17 | 2026-08-05 |
| VRDN | Director | — | $21.24 | — | $0 | 7 | 2026-07-02 |
| EWTX | Director | — | $44.40 | — | $0 | 4 | 2026-06-17 |
| VIVEVE MEDICAL, INC. (VIVE) Delisted | Director | 2 | $0.00 | $0 | $0 | 13 | 2023-01-05 |
| Cogent Biosciences, Inc. (UMRX) Delisted | Director | — | — | — | $0 | 2 | 2020-06-11 |
| Viridian Therapeutics, Inc.\DE (MGEN) Delisted | Director | — | — | — | $0 | 3 | 2020-05-22 |
| Dimension Therapeutics, Inc. (DMTX) Delisted | Director | — | — | — | $0 | 3 | 2017-11-07 |
| VIVEVE MEDICAL, INC. (TCON) Delisted | Director | — | $0.03 | — | $0 | 1 | 2016-05-20 |
| ALBIREO PHARMA, INC. (BIOD) Delisted | Director | — | — | — | $0 | 2 | 2016-03-08 |
| MNOV | Director | 1,000 | $1.81 | $1.8K | -$28.9K | 7 | 2013-05-23 |
| AFFYMAX INC (AFFY) Delisted | CEO | 75,000 | — | — | -$16.32M | 18 | 2010-09-24 |
Recent Filings
85 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-31 | COGT | Mixed | — | -$1.44M | EDGAR |
| 2026-08-27 | COGT | Notice (144) | −45,510 | -$1.67M | EDGAR |
| 2026-08-05 | PTN | Trust (Z) | — | $0 | EDGAR |
| 2026-07-02 | VRDN | Grant (A) | — | $0 | EDGAR |
| 2026-06-17 | EWTX | Grant (A) | — | $0 | EDGAR |
| 2026-06-11 | COGT | Grant (A) | — | $0 | EDGAR |
| 2025-12-11 | PTN | Grant (A) | — | $0 | EDGAR |
| 2025-07-02 | VRDN | Grant (A) | — | $0 | EDGAR |
| 2025-06-18 | EWTX | Grant (A) | — | $0 | EDGAR |
| 2025-06-05 | COGT | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.